Targets › ACADM
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Jan 2028.
Medium-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation (FAO), breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats. The first step of FAO consists in the proR-proR stereospecific alpha, beta-dehydrogenation of fatty acyl-CoA thioesters using the electron transfer flavoprotein (ETF)…. (UniProt, P11310)
Open in Phaseline: the race on ACADM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jerry Vockley, MD, PhD | Sodium phenylbutyrate (ACER-001) Nitrogen scavenger; ammonia-lowering agent that may stabilize or improve mutant ACADM prot | ACADM | Phase 2 | Medium-chain Acyl-CoA Dehydrogenase Deficiency | Jan 2028 |
Medium-chain Acyl-CoA Dehydrogenase Deficiency (1)
small molecule (1)
Jerry Vockley, MD, PhD (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.